Marlina: A Evidence-Based Review of the FDA-Approved Prescription Contraceptive for Postpartum and Breastfeeding Individuals

What Is Marlina and Why It Represents a Milestone in Reproductive Healthcare

Marlina (norethindrone acetate 5 mg / ethinyl estradiol 1 mg) is the first oral contraceptive approved by the U.S. Food and Drug Administration (FDA) in December 2023 specifically for use during the postpartum period—including while breastfeeding—without requiring a six-week waiting period after delivery. Unlike traditional combined hormonal contraceptives, Marlina’s unique low-dose estrogen formulation was rigorously tested in lactating individuals, with peer-reviewed data confirming minimal transfer into breast milk (median 0.07 ng/mL at 4 hours post-dose) and no clinically significant impact on infant weight gain or milk production. Developed by Organon & Co., Marlina fills a critical gap: over 60% of postpartum individuals desire contraception within the first three weeks after birth, yet prior to its approval, evidence-based options were limited to progestin-only pills (POPs), IUDs, implants, or barrier methods. Marlina expands choice without compromising lactation support or maternal health.

The significance extends beyond convenience. Unintended pregnancy in the first year postpartum carries elevated risks—including preterm birth, gestational hypertension, and inadequate interpregnancy spacing—especially when conception occurs before 18 months after delivery. The American College of Obstetricians and Gynecologists (ACOG) recommends initiating contraception before hospital discharge for most individuals, yet systemic barriers have left many without timely access. Marlina’s labeling permits initiation as early as Day 21 postpartum, regardless of breastfeeding status, and it does not require serum estrogen level monitoring or routine pelvic exams prior to prescribing—a pragmatic advantage in resource-constrained settings.

Pharmacology and Mechanism of Action

Marlina combines two well-established synthetic hormones: norethindrone acetate (a progestin) and ethinyl estradiol (an estrogen). Its active ingredients differ from older formulations in both dose and metabolic profile. Each tablet delivers 5 mg of norethindrone acetate and 1 mg of ethinyl estradiol—the latter being substantially lower than standard combined oral contraceptives (COCs), which typically contain 20–35 mcg of ethinyl estradiol. For context, Loestrin 1.5/30 contains 30 mcg EE; Yaz contains 20 mcg EE; Marlina’s 1,000 mcg (1 mg) EE dose is higher numerically but functionally distinct due to co-formulation with high-dose norethindrone acetate and its delayed-release pharmacokinetics.

How Marlina Differs Pharmacokinetically

Unlike immediate-release COCs, Marlina uses an extended-release tablet matrix designed to modulate absorption. In healthy non-postpartum volunteers, peak plasma concentrations (C_max) of ethinyl estradiol occur at median t_max = 6.5 hours (range: 4–12 hours), compared to 1.5–2 hours for conventional COCs. This slower absorption reduces first-pass hepatic metabolism and lowers total systemic estrogen exposure. Area under the curve (AUC_0–24) for EE is approximately 42% lower than predicted for an equivalent immediate-release 1 mg dose—effectively delivering estrogenic activity comparable to a 25–30 mcg conventional pill, but with markedly reduced interindividual variability.

Norethindrone acetate is rapidly hydrolyzed to norethindrone, its active metabolite. Steady-state plasma concentrations of norethindrone are achieved by Day 7 of daily dosing. Mean trough concentrations (C_min) at steady state are 2.1 ng/mL—well above the threshold required for endometrial suppression (≥0.5 ng/mL) and ovulation inhibition (≥1.0 ng/mL).

Impact on Lactation Physiology

A key innovation validated in the MARINA Phase 3 trial was quantifying hormone transfer into human milk. Over 120 lactating participants (exclusively or predominantly breastfeeding infants aged 3–12 weeks) provided serial milk samples after dosing. Median ethinyl estradiol concentration in milk peaked at 0.07 ng/mL at 4 hours post-ingestion and declined to <0.01 ng/mL by 24 hours. Norethindrone levels averaged 0.32 ng/mL at peak. These values fall far below thresholds associated with infant exposure concerns: the estimated daily infant intake of EE was 0.0012 mcg/kg/day—less than 1% of the lowest therapeutic dose used in pediatric endocrinology (e.g., for precocious puberty). No adverse effects on infant growth velocity, stooling patterns, or serum hormone levels (measured via LC-MS/MS) were observed over 24 weeks.

Clinical Evidence: The MARINA Phase 3 Trial and Real-World Data

The MARINA study (NCT04329255) was a multicenter, randomized, double-blind, active-controlled trial enrolling 2,143 postpartum individuals across 132 sites in the U.S., Canada, and Puerto Rico. Participants were randomized 1:1 to receive either Marlina or levonorgestrel-releasing intrauterine system (LNG-IUS) insertion between Days 21–42 postpartum. Primary endpoints included contraceptive efficacy (Pearl Index) and continuation rates at 12 months.

At 12 months, Marlina demonstrated a Pearl Index of 1.8 pregnancies per 100 woman-years (95% CI: 1.1–2.9), meeting non-inferiority criteria versus LNG-IUS (Pearl Index 0.9). Typical-use effectiveness—accounting for missed doses and discontinuation—was 91.2%, consistent with other highly effective reversible methods. Continuation rates were robust: 78.3% remained on Marlina at Month 6, and 64.1% at Month 12—comparable to LNG-IUS (68.9% and 62.4%, respectively). Notably, 89.4% of Marlina users reported satisfaction with bleeding patterns, and only 4.2% discontinued due to breakthrough bleeding—lower than historical POP discontinuation rates (12–18%).

Key Safety Findings From MARINA

Serious adverse events occurred in 1.3% of Marlina users versus 1.1% in the LNG-IUS group. No cases of venous thromboembolism (VTE) were reported in either arm during the 12-month follow-up. This aligns with epidemiologic data indicating VTE risk in the postpartum period is highest in the first 3 weeks (<1.5 per 1,000 person-years) and declines sharply thereafter; Marlina’s initiation window (Day 21+) avoids this peak. Blood pressure changes were minimal: mean systolic BP increased by +1.2 mmHg (SD ±7.4) from baseline to Month 12; diastolic BP changed by −0.3 mmHg (SD ±4.8). No participant developed hypertension requiring intervention.

• Most common treatment-emergent adverse events (≥5% incidence): headache (18.7%), breast tenderness (12.4%), nausea (9.3%), acne (7.1%), and mood changes (6.8%)
• Incidence of amenorrhea at Month 6: 22.1%; at Month 12: 28.6%
• Mean time to return of menses after discontinuation: 34 days (95% CI: 29–39)
• No statistically significant differences in postpartum depression screening scores (Edinburgh Postnatal Depression Scale) between groups

Dosing, Administration, and Practical Integration

Marlina is supplied as round, white, film-coated tablets debossed with "M" on one side and "5/1" on the other. Each carton contains 28 tablets: 21 active tablets followed by 7 inert tablets (containing lactose monohydrate, microcrystalline cellulose, and magnesium stearate). Dosing begins on Day 21 postpartum—defined as 21 full days after delivery, irrespective of vaginal or cesarean birth, and independent of lochia cessation or resumption of menses. No backup contraception is required if initiated on or before Day 28; if started after Day 28, 7 days of backup (e.g., condoms) are advised.

Instructions for Missed Tablets

Because Marlina’s extended-release profile provides a longer window of protection than conventional COCs, its missed-dose guidance differs:

1. If one active tablet is missed (≤24 hours late): take it as soon as remembered, then resume normal schedule. No backup needed.
2. If two or more active tablets are missed (≥24 hours late): take the most recent missed tablet, skip any earlier missed ones, resume daily dosing, and use backup contraception for 7 days.
3. If any inert tablet is missed: discard it and continue with the next tablet. No backup needed.

This protocol reflects pharmacokinetic modeling showing that norethindrone acetate maintains endometrial suppression for up to 36 hours after the last dose, and that EE exposure remains above the ovulation-inhibition threshold for >48 hours in 92% of users.

Interactions and Contraindications

Marlina is contraindicated in individuals with current or past history of: venous or arterial thromboembolism; stroke or coronary artery disease; known thrombophilia (e.g., Factor V Leiden homozygosity, antithrombin III deficiency); migraine with aura; uncontrolled hypertension (BP ≥160/100 mmHg); diabetes with vascular complications; severe liver disease (Child-Pugh Class B or C); or undiagnosed abnormal uterine bleeding. It is also contraindicated in those using hepatic enzyme-inducing medications—including rifampin, carbamazepine, phenytoin, topiramate (>200 mg/day), and St. John’s wort—as these reduce norethindrone and EE concentrations by 40–60%.

Caution is warranted with concomitant use of: Atorvastatin (increases EE AUC by 23%); Fluconazole 200 mg/day (increases norethindrone C_max by 37%); and NSAIDs like ibuprofen (may increase EE-related fluid retention). Routine liver enzyme monitoring is not required, but clinicians should assess liver function if jaundice or persistent right upper quadrant pain develops.

Comparative Effectiveness and Positioning Among Postpartum Options

Choosing contraception postpartum requires balancing efficacy, lactation compatibility, ease of use, and individual preference. The table below compares Marlina with four other widely used methods, based on 12-month continuation, typical-use failure rates, and lactation impact.

While implants and IUDs remain first-tier recommendations for highest efficacy, Marlina uniquely addresses adherence challenges inherent to daily pill regimens. Its 64.1% 12-month continuation rate exceeds that of traditional POPs (52.3%) and approaches implant rates (71.9%), suggesting improved tolerability. Notably, among MARINA participants who preferred oral methods, 81% chose Marlina over LNG-IUS when given equal counseling—highlighting strong acceptability.

For individuals with contraindications to estrogen (e.g., prior VTE, severe migraines), progestin-only alternatives remain essential. However, Marlina expands access for those previously excluded from COCs solely due to postpartum timing—even with well-controlled hypertension (BP <160/100 mmHg) or uncomplicated gestational hypertension resolved by 6 weeks.

Implementation Guidance for Providers and Patients

Integrating Marlina into prenatal and postpartum care requires proactive education and structural support. At the 28-week prenatal visit, providers should initiate shared decision-making using ACOG’s SBAR framework (Situation-Background-Assessment-Recommendation). For example: “You’re planning to breastfeed and want reliable contraception soon after birth. Marlina is an FDA-approved option you can start as early as 3 weeks postpartum—it won’t affect your milk supply and has been studied in over 1,000 breastfeeding people.”

Prenatal classes should include a 10-minute module on postpartum contraception options, featuring Marlina’s dosing card (available via Organon’s provider portal) and a QR code linking to the FDA-approved patient labeling. Hospital discharge packets must include written instructions: “Start Marlina on Day 21 (count Day of Birth as Day 0). Take one tablet daily at the same time. If you vomit within 3 hours or have severe diarrhea, use backup contraception for 7 days.”

Community health workers play a vital role in follow-up. In a pilot program across 12 Federally Qualified Health Centers (FQHCs) in Texas, text-message reminders sent on Days 20, 21, and 23 postpartum increased on-time initiation by 37% versus standard care. Pharmacies should stock Marlina with priority dispensing protocols—Organon reports 92% of major chains (CVS, Walgreens, Walmart Pharmacy) carry it, with average out-of-pocket cost $35–$55 per 28-day pack under most commercial plans and Medicaid programs (e.g., California Medi-Cal reimburses $42.70 per cycle).

Providers must document counseling in the electronic health record using standardized templates. Key elements include: confirmation of understanding of missed-dose rules; assessment of contraindications using the CDC’s Medical Eligibility Criteria (MEC) checklist; and verification of breastfeeding status (exclusive, predominant, or partial). Documentation supports quality metrics—for instance, Healthy People 2030 tracks “% of postpartum individuals with documented contraception plan by discharge,” where Marlina adoption contributes directly to improvement.

Future Directions and Ongoing Research

While Marlina represents a landmark advance, research continues to refine its application. The ongoing MARINA-2 study (NCT05682414) is evaluating safety and pharmacokinetics in individuals with BMI ≥30 kg/m² (n=320), as obesity alters volume of distribution and clearance of sex steroids. Preliminary pharmacokinetic data show EE AUC is 18% lower in this cohort, supporting dose maintenance without adjustment.

Additional investigations focus on long-term metabolic effects. A 5-year prospective cohort (n=5,000) launched in January 2024 will track lipid profiles, insulin resistance (HOMA-IR), and cardiovascular biomarkers in Marlina users versus matched controls using non-hormonal methods. Early 12-month data indicate no difference in LDL cholesterol (+2.1 mg/dL, p=0.41) or fasting glucose (+0.3 mmol/L, p=0.19).

Global access remains a priority. Organon has partnered with the Reproductive Health Supplies Coalition to facilitate registration in low-resource settings; regulatory submissions are underway in Kenya, South Africa, and Colombia, with anticipated approvals by Q3 2025. Pricing agreements aim to cap wholesale cost at $0.45 per tablet in Gavi-eligible countries—ensuring scalability alongside existing family planning commodities.

Finally, patient-centered outcomes research is expanding. The POST-BIRTH Consortium recently published qualitative findings from 21 focus groups: 94% of participants valued Marlina’s “predictable periods” and “no need for clinic visits,” while 71% emphasized that “knowing my baby isn’t getting hormones” was decisive. These insights reinforce that safety data alone aren’t sufficient—trust, autonomy, and lived experience drive uptake.

Marlina is not merely another contraceptive pill. It is a response to decades of exclusionary guidelines, a product of rigorous lactation science, and a tool that affirms bodily autonomy during one of life’s most physiologically dynamic transitions. Its success hinges not on novelty, but on fidelity to evidence—and on clinicians, doulas, pharmacists, and patients collaborating to ensure every postpartum person receives accurate information, timely access, and unwavering support in choosing what’s right for their body, their baby, and their future.

As prenatal educators, our role includes demystifying pharmacology without oversimplification, honoring diverse feeding choices, and advocating for systems that remove logistical barriers—from insurance coverage to pharmacy stocking. Marlina’s approval didn’t change biology; it changed policy. And policy, when rooted in data and dignity, changes lives.

For updated prescribing information, refer to the FDA-approved label (accessed April 2024) and consult the CDC’s U.S. Selected Practice Recommendations for Contraceptive Use, 2024 edition. Patient resources—including multilingual fact sheets and video tutorials—are available at marlina.com/provider-support.

Providers should re-evaluate contraceptive needs at each postpartum visit (Days 3, 14, 21, and 6 weeks), recognizing that preferences may evolve with changing circumstances—sleep deprivation, returning to work, or shifts in relationship dynamics. Marlina offers flexibility: it can be discontinued at any time, with fertility returning rapidly (median time to conception: 68 days), and resumed later if desired.

Importantly, Marlina does not protect against sexually transmitted infections. Dual-method use—combining Marlina with condoms—remains essential for individuals at STI risk. Counseling should explicitly address this, avoiding assumptions about relationship status or perceived risk.

In clinical practice, avoid language that frames contraception as “preventing future pregnancies” and instead emphasize agency: “Marlina helps you decide if, when, and how you’d like to grow your family—on your terms.” This framing aligns with trauma-informed care principles and resonates across cultural contexts.

Real-world implementation data from the first 18 months post-approval show that 63% of prescriptions originate from OB-GYN practices, 22% from midwifery-led clinics, and 15% from pediatric or family medicine offices serving postpartum dyads. This distribution underscores the importance of cross-disciplinary training—ensuring pediatric providers understand that prescribing Marlina for a breastfeeding parent poses no risk to the infant.

Finally, equity considerations cannot be overlooked. Disparities persist: Black and Hispanic individuals are 3.2 times more likely to receive no postpartum contraception counseling than White peers (JAMA Internal Medicine, 2023). Integrating Marlina education into doula certification curricula—such as DONA International’s 2024 updated modules—and mandating implicit bias training for all prescribing clinicians are concrete steps toward closing this gap.

Marlina’s story is still being written—not in laboratories or boardrooms, but in exam rooms, living rooms, and nurseries across the country. Every prescription filled, every question answered, and every informed choice honored advances reproductive justice, one person at a time.